ClinicalTrials.gg
Not yet recruitingNCT07629193TH-CHCUpdated Jun 5, 2026

Liver Transplant for Hepatocellular Carcinoma

An observational study in Hepatocellular Carcinoma (HCC) and Liver Transplantation (LT), sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
562
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Carcinoma, Hepatocellular by Assistance Publique - Hôpitaux de Paris — 16 open to participants now, 20 under way, 1 of them phase 3. Carcinoma, Hepatocellular · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
7th of 15
562 · median 372
Started
2026
with 2 others
Observational
15 of 41
7 open now
Primary completion
2027-01
later than 6 of 19 live
Registered
40th of 41
by date

Among the 41 studies in Carcinoma, Hepatocellular by Assistance Publique - Hôpitaux de Paris, this one is the 7th largest by planned enrollment of the 15 observational ones that give a count, is one of 3 that started in 2026, is one of 15 observational ones, reaches primary completion later than 6 of the 19 other live ones, and was the 40th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

16 of the 41 studies in Carcinoma, Hepatocellular by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Carcinoma, Hepatocellular by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

This research focuses on analysing data collected as part of your usual care. Currently, the eligibility of patients with hepatocellular carcinoma for liver transplantation is based on the calculation of scores. These scores mainly take into account the volume of the tumour measured by imaging, one or more blood markers and the patient's general condition.

However, these scores do not take into account:

  • the concept of downstaging (i.e. the prior reduction of tumour volume through locoregional or systemic treatments, which subsequently allows access to LT), which is becoming increasingly widespread
  • the dynamics of hepatocellular carcinoma (tumour recurrence while waiting on the transplant list, administration of wait-and-see treatments)
  • certain anatomopathological parameters (such as the macro-trabecular subtype of HCC).

The aim of our study is to develop a new score incorporating these factors in order to identify patients with hepatocellular carcinoma who could truly benefit from a liver transplant.

To answer the question posed in the research, data will be collected from 402 people who received a liver transplant for hepatocellular carcinoma at three hospitals in the Paris region between 1 January 2018 and 31 December 2023, and from 160 people at two international hospitals in Canada and Belgium.

Read the detailed description

Hepatocellular carcinoma (HCC) is a major public health problem. It is the fifth most common cancer and the third leading cause of cancer death worldwide. Its prevalence continues to increase and mortality associated with HCC remains high, unlike the overall cancer mortality rate. Liver transplantation (LT) remains the only curative treatment option that addresses both the tumour disease and the underlying liver disease. However, this approach presents a major challenge: the occurrence of tumour recurrence after LT, which is highly morbid. Rigorous selection for LT of candidates with HCC is essential and is currently based on standardised scores, such as AFP, Milan or Up to Seven scores, which take into account tumour volume and the patient's general condition prior to LT.

The recent arrival of immunotherapy in the management of advanced HCC has opened up new prospects for LT. In particular, the question arises as to whether LT should be offered to patients initially diagnosed with advanced HCC who have benefited from downstaging treatments, including immunotherapy.

At the same time, due to the shortage of transplants, waiting times on the LT list are getting longer in some countries and patients are increasingly receiving expectant management for their HCC. They are exposed to the risk of HCC progression or recurrence while on the list, ruling out any possibility of subsequent LT. Certain histological subtypes of HCC, particularly macrotrabecular HCC, have recently been identified as being associated with a poor prognosis, but little data is available on the risk of recurrence of these HCCs after LT raising questions about the relevance of LT for these patients.

Finally, the impact of the choice of immunosuppression on the risk of HCC recurrence after LT remains largely unexplored.

Main objective:

In accordance with TRIPOD recommendations (40), the objective is to improve the predictive scores for LT failure in patients with HCC by analysing biological, clinical, imaging and anatomopathological parameters at enrolment. This score will also include the number and type of HCC recurrences, as well as the associated expectant management. The objective is to determine the threshold of predictive score for achieving a probability of LT failure in patients of less than 20%.

Secondary objectives:

  • To study overall survival and recurrence-free survival in patients with a selection score with a previously identified LT failure target (defined as removal from the LT list or recurrence after LT) \<20%.
  • To compare the performance of different selection scores for LT eligibility (AFP score, Milan score, Up-to-Seven, newly identified score) on LT failure rate, overall survival and recurrence-free survival in patients with HCC.
  • To assess the impact of HCC recurrence and watchful waiting on TH failure rate, overall survival and recurrence-free survival in HCC patients on the LT list.
  • To assess the impact of HCC subtypes, particularly macro-trabecular HCC, on LT failure rates, overall survival and recurrence-free survival in patients on the LT waiting list.
  • To assess the impact of underlying liver disease etiology and the presence of portal hypertension on LT failure rates, overall survival and recurrence-free survival in patients on the LT waiting list.
  • To assess the impact of modulating immunosuppressive therapy on the risk of recurrence and the occurrence of rejection in patients transplanted for HCC.
03

Conditions studied

  • Hepatocellular Carcinoma (HCC)
  • Liver Transplantation (LT)

Keywords

  • predictive score
  • Liver Transplantation (LT)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

We will retrospectively include patients who underwent LT for HCC between 1 January 2018 and 31 December 2023 in the Paris, Montreal and Brussels centres.

The derivation cohort will include patients from the AP-HP, while the validation cohort will include patients from the centres in Montreal and Brussels.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults (≥18 years).
  2. Underwent LT for HCC between January 1, 2018 and December 31, 2023.

Exclusion criteria

Exclusion Criteria

  1. No evidence of HCC (imaging or histology).
  2. LT performed for another intrahepatic tumor other than HCC.
  3. The patient's objection to the use of their data.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
562 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Failure of liver transplantation (LT)

    Failure of LT is defined as the occurrence of one of the following events: (i) removal from the transplant waiting list, (ii) recurrence of HCC post-LT, or (iii) death.

    Time frame: Up to 7 years after LT

Secondary outcomes

  1. Overall survival

    Time frame: Up to 7 years after LT

  2. Recurrence-free survival

    Time frame: Up to 7 years after LT

  3. Occurrence of acute cellular rejection

    Time frame: Up to 7 years after LT

  4. Correlation of LT failure rate, overall survival and recurrence-free survival with biological, clinical, imaging and anatomopathological parameters (macro-trabecular subtype) at enrolment and on the day of LT

    Time frame: Up to 7 years after LT

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jan 2027, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
Jun 5, 2026
StartEst.
Jun 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07629193
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jun 5, 2026

Study contacts

Manon Allaire, MD
Contact
manon.allaire@aphp.fr
+33 1 42 16 10 34
Héloïse Giudicelli, MD
Contact
heloise.giudicelli@gmail.com
Manon Allaire, MD
study chair · Assistance Publique - Hôpitaux de Paris
Héloïse Giudicelli, MD
study director · Sorbonne University, Paris, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion